Michael J Mitchell
Overview
Explore the profile of Michael J Mitchell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
176
Citations
6604
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Swingle K, Hamilton A, Safford H, Geisler H, Thatte A, Palanki R, et al.
Nature
. 2024 Dec;
637(8045):412-421.
PMID: 39663452
Pre-eclampsia is a placental disorder that affects 3-5% of all pregnancies and is a leading cause of maternal and fetal morbidity worldwide. With no drug available to slow disease progression,...
12.
Mukalel A, Hamilton A, Billingsley M, Li J, Thatte A, Han X, et al.
Adv Funct Mater
. 2024 Dec;
34(27).
PMID: 39628840
Chimeric antigen receptor (CAR) monocyte and macrophage therapies are promising solid tumor immunotherapies that can overcome the challenges facing conventional CAR T cell therapy. mRNA lipid nanoparticles (mRNA-LNPs) offer a...
13.
Han X, Alameh M, Xu Y, Palanki R, El-Mayta R, Dwivedi G, et al.
Nat Biomed Eng
. 2024 Nov;
8(11):1412-1424.
PMID: 39578640
Ionizable lipids largely determine the biocompatibility of lipid nanoparticles (LNPs) and the efficacy for mRNA delivery. Rational design and combinatorial synthesis have led to the development of potent and biodegradable...
14.
Mossburg K, Shepherd S, Barragan D, O N, Berkow E, Maidment P, et al.
Eur J Nucl Med Mol Imaging
. 2024 Nov;
52(3):1177-1188.
PMID: 39528844
Purpose: Ultrasmall silver sulfide nanoparticles (AgS-NP) have been identified as promising contrast agents for a number of modalities and in particular for dual-energy mammography. These AgS-NP have demonstrated marked advantages...
15.
Yoon I, Xue L, Chen Q, Liu J, Xu J, Siddiqui Z, et al.
Angew Chem Int Ed Engl
. 2024 Oct;
64(3):e202415389.
PMID: 39379320
Nucleic acid delivery with mRNA lipid nanoparticles are being developed for targeting a wide array of tissues and cell types. However, targeted delivery to the bone microenvironment remains a significant...
16.
Xue L, Zhao G, Gong N, Han X, Shepherd S, Xiong X, et al.
Nat Nanotechnol
. 2024 Oct;
20(1):132-143.
PMID: 39354147
Systemic delivery of messenger RNA (mRNA) for tissue-specific targeting using lipid nanoparticles (LNPs) holds great therapeutic potential. Nevertheless, how the structural characteristics of ionizable lipids (lipidoids) impact their capability to...
17.
Mrksich K, Padilla M, Mitchell M
Adv Drug Deliv Rev
. 2024 Sep;
214:115446.
PMID: 39293650
In the past decade, nucleic acid therapies have seen a boon in development and clinical translation largely due to advances in nanotechnology that have enabled their safe and targeted delivery....
18.
Kim E, Teerdhala S, Padilla M, Joseph R, Li J, Haley R, et al.
Eur J Immunol
. 2024 Sep;
54(12):e2451008.
PMID: 39279550
Lipid nanoparticles (LNPs) have emerged as the preeminent nonviral drug delivery vehicles for nucleic acid therapeutics, as exemplified by their usage in the mRNA COVID-19 vaccines. As a safe and...
19.
Gong N, Zhong W, Alameh M, Han X, Xue L, El-Mayta R, et al.
Nat Mater
. 2024 Sep;
23(12):1736-1747.
PMID: 39223270
Nanoparticles are promising for drug delivery applications, with several clinically approved products. However, attaining high nanoparticle accumulation in solid tumours remains challenging. Here we show that tumour cell-derived small extracellular...
20.
Swingle K, Hamilton A, Mitchell M
Placenta
. 2024 Aug;
PMID: 39181830
Clinically approved therapeutics for obstetric conditions are extremely limited, with over 80% of drugs lacking appropriate labeling information for pregnant individuals. The pathology for many of these obstetric conditions can...